|1.||Couture, Réjean: 9 articles (01/2012 - 04/2002)|
|2.||Calixto, J B: 8 articles (01/2013 - 10/2001)|
|3.||Bader, Michael: 8 articles (10/2011 - 12/2002)|
|4.||Calixto, João B: 6 articles (12/2012 - 12/2002)|
|5.||Ongali, Brice: 6 articles (12/2005 - 04/2002)|
|6.||Parton, Roger: 5 articles (06/2012 - 07/2002)|
|7.||Scharfstein, Julio: 5 articles (03/2012 - 11/2006)|
|8.||Ferreira, J: 5 articles (05/2008 - 10/2001)|
|9.||Zamri-Saad, M: 4 articles (11/2015 - 10/2006)|
|10.||Campos, M M: 4 articles (08/2013 - 10/2001)|
04/01/2014 - "Pain intensity was measured on a 100-mm non-graduated visual analogue scale (VAS), and it was significantly greater in group A (8 mm) than that in group B (2 mm). "
01/01/1991 - "Comparing the percentage of dysmenorrhoea it emerges: 1) that dysmenorrhoea is present in a lower percentage in subjects in Group A (68.19%) in respect to women in Group B; 2) that in a considerable number of girls in Group B it was observed that there was a regression or an improvement in the pain symptomatology after the beginning in athletic activity; 3) dysmenorrhoea was much less in the more intense the sports activity (Groups C and D). "
10/01/2011 - "[Twenty-one cases of pain caused by earthquake treated mainly with acupuncture at Jiaji (EX-B 2)]."
10/19/2001 - "This review summarizes the most recent data from various animal models which convey support for a role of B(2) receptors in the acute phase of the inflammatory and pain response, and for a role of B(1) receptors in the chronic phase of the response. "
10/01/2001 - "The gathering of results has demonstrated that both B(1) and B(2) receptors seem to exert a meaningful role during nociceptive responses, the B(1) receptor being most relevant in the chronic stages of inflammatory pain. "
|2.||Hemorrhagic Septicemia (Haemorrhagic Septicemia)
12/01/2007 - "Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves."
08/18/2012 - "The efficacy of an intranasal haemorrhagic septicaemia vaccine containing live gdhA derivative Pasteurella multocida B:2 was tested in buffaloes in Sabah. "
08/18/2012 - "Efficacy of intranasal vaccination of field buffaloes against haemorrhagic septicaemia with a live gdhA derivative Pasteurella multocida B:2."
01/01/2011 - "Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats."
03/01/2005 - "Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration."
04/01/1991 - "Histopathologic evaluations revealed that a) SMC had no effect; b) 2- and 5-day T cells, injected at E:T ratios greater than 5:1, caused significant reduction in tumor size; and c) 2- or 5-day T cells, at a 40:1 E:T ratio, resulted in little or no histologic evidence of tumor. "
12/01/2015 - "In group B, 2 patients are alive with NED, 1 patient is alive with disease, and the remaining 12 patients have died a tumor-related death. "
11/25/2015 - "When tested against the normal cells (NIH/3T3), caseagrewifolin B (2) exhibited a significant selective inhibition against cancer cells in comparison with the normal cells. "
03/27/2015 - "Companeramides A (1) and B (2) showed high nanomolar in vitro antiplasmodial activity but were not overtly cytotoxic to four human cancer cell lines at the doses tested."
08/22/2014 - "Trichormamide B (2) was cytotoxic against MDA-MB-435 and HT-29 cancer cell lines with IC50 values of 0.8 and 1.5 μM, respectively."
01/01/2011 - "The results presented here will serve as priors for the design of further studies to test the efficacy of the concept with stroke patients, and the found effects will provide a basis for the development of a classifier for a future B(2)RI."
10/01/2006 - "The aim of the current study was therefore to investigate the effect of delayed B(2) receptor inhibition on morphological and functional outcome following experimental stroke. "
04/01/2014 - "In group A 6 (3.5%) patients developed stroke where as in group-B 2 (1.5%) patients developed stroke out of these 6 patients there were 2 mortalities after stroke in group-A while in group-B there was no mortality after stroke within 30 days postoperatively. "
02/01/2010 - "The patterns and densities of PAR(2) and B(2) immunoreactivity in frozen MCA sections were not altered with stroke. "
10/01/2006 - "Our data therefore suggest that inhibition of kinin B(2) receptors represents a treatment strategy for ischemic stroke which may warrant clinical validation."
01/01/2013 - "Our results suggest that, in the absence of B(2)R, both B(1)R and AT(2)R play important compensatory roles in preventing deterioration of cardiac function and remodelling post-MI possibly via suppression of inflammation, TGFβ(1) and ERK1/2 signalling."
05/01/2010 - "Treatment with a selective B(2)R agonist initiated at the time of induction of acute MI in mice had a beneficial effect on cardiac function, tissue remodeling, and inflammation-related tissue gene expression, which may explain its structural and functional benefits."
07/01/2003 - "The components of the kinin system, including kinongens, kininogenases, and B(2) and B(1) receptors, are expressed and activated during inflammation. "
05/01/2002 - "BK B(2) receptor antagonists may prove useful for the treatment of pathological situations caused by excessively increased local kinin concentrations, such as inflammation, tissue injury and pain. "
01/01/2013 - "Blockade of AT(2)R or B(1)R worsened cardiac remodelling, hypertrophy and dysfunction associated with increased inflammation and ERK1/2 phosphorylation and decreased NO excretion in B(2)R(-/-) mice, which were exacerbated by dual blockade of B(1)R and AT(2)R. "
|7.||(4- amino- 5- (4- (4- (2,4- dichloro- 3- (2,4- dimethyl- 8- quinolyloxymethyl)phenylsulfonamido)tetrahydro- 2H- 4- pyranoylcarbonyl)piperazino)- 5- oxopentyl)(trimethyl)ammonium
|8.||Ammonium Chloride (Sal Ammoniac)
|10.||Proteins (Proteins, Gene)
|1.||Drug Therapy (Chemotherapy)